Allarity Therapeutics Inc. (ALLR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, ALLR scores 31 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 4 out of 20, reflecting ROIC of -35% and FCF yield of 0%; for a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow to support valuation. The whale 13F flow pillar scores 3 out of 20 (institutional accumulation and options positioning), suggesting weak institutional support in the source data. The insider conviction pillar scores 5 out of 20 (SEC Form 4 and Congressional PTR cluster flow), indicating limited insider-side confirmation. The macro regime fit pillar scores 9 out of 20, with a beta of 1.0 and sector sensitivity noted. The forensic balance sheet pillar scores 10 out of 20, citing an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. Taken together, the pillars point to deteriorating cash generation, weak ownership signals, and a constrained balance-sheet profile. Upside drivers in this framework are limited to the stock's depressed price and any future operational turnaround, which the source data does not establish; valuation multiples such as P/E and EV/EBITDA are not available in source data, so relative valuation cannot be assessed.

Per the SEC financials, the company reported operating losses in all three periods and free cash flow outflows in each. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported cash declined from $19.5M to $14.7M between FY 2024 and FY 2025.

Per the news wire, recent items include: a Tumim stock purchase agreement ending ($6 million agreement, per headline); coverage describing resale coverage surviving the termination; and a first commercial CLIA laboratory services agreement described as a potential path to recurring revenue. Several items carry a YELLOW light and "MARKET WIRE" impact label. Risk watch items include the termination of the Tumim agreement and the company's zero reported revenue. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. Investors should note that the only sector context provided is the Health Care classification and a beta of 1.0.

• What specific products or services, and which customers, generate the CLIA laboratory services revenue referenced in the news wire?
• What are the terms and amounts of the Tumim agreement, and what were the reasons for its termination?
• Where does the company's cash runway stand given cash of $14.7M against FY 2025 free cash flow of $-14.8M?
• What are the reported debt figures, which are shown as N/A across all periods?
• Which institutions or insiders hold ALLR shares, given that holder data is unavailable?